Bio­gen scut­tles a Tysabri pro­gram af­ter the drug fails stroke test, thin­ning the pipeline

Bio­gen’s hopes of ex­pand­ing its fran­chise for Tysabri (na­tal­izum­ab) by break­ing in­to is­chemic stroke just flopped, leav­ing the big biotech with one less pro­gram in an al­ready thin pipeline.

In­ves­ti­ga­tors for Bio­gen $BI­IB say that the drug failed the pri­ma­ry and sec­ondary end­points in a Phase IIb tri­al, of­fer­ing con­vinc­ing da­ta that the drug would not work for this in­di­ca­tion. The hard da­ta will be held back for a sci­en­tif­ic con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER